Takeda Presents Azilsartan Medoxomil Phase 3 Studies Results
Results were statistically significant and showed that azilsartan medoxomil (80 mg/day) lowered 24-hour SBP by ambulatory blood pressure monitoring (ABPM), the primary endpoint, in head-to-head trials with the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.